Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer’s Disease
- 27 December 2016
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 8 (3) , 638-661
Abstract
A novel systems therapeutics approach, involving simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylase (HDAC), has been validated as a potentially novel therapeutic strategy for the treatment of Alzheimer´s disease (AD). First-in-class dual inhibitors bearing a sildenafil core have been very recently reported, and the lead molecule, CM-414 (7), has proven this strategy in AD animal models. Because scaffolds may play a critical role in primary activities and ADME-Tox profiling as well as on intellectual property, we have explored alternative scaffolds (vardenafil- and tadalafil-based cores) and evaluated their impact on critical parameters such as primary activities, permeability, toxicity and in-vivo (pharmacokinetics and functional response in hippocampus) to identify a potential alternative lead molecule bearing a different chemotype for in-vivo testing.Keywords
Funding Information
- Ministerio de Economía y Competitividad (11/02861, 14/01244, FIS PI12/00710)
- Universidad de Navarra
- Foundation for Applied Medical Research, University of Navarra
This publication has 43 references indexed in Scilit:
- Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell ViabilityJournal of Biological Chemistry, 2013
- Class I HDACs Share a Common Mechanism of Regulation by Inositol PhosphatesMolecular Cell, 2013
- Fragment-Hopping-Based Discovery of a Novel Chemical Series of Proto-Oncogene PIM-1 Kinase InhibitorsPLOS ONE, 2012
- An epigenetic blockade of cognitive functions in the neurodegenerating brainNature, 2012
- Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer's diseaseBritish Journal of Pharmacology, 2011
- HDAC3 Is a Critical Negative Regulator of Long-Term Memory FormationThe Journal of Neuroscience, 2011
- HDAC2 negatively regulates memory formation and synaptic plasticityNature, 2009
- Deregulation of HDAC1 by p25/Cdk5 in NeurotoxicityNeuron, 2008
- Conformational Variations of Both Phosphodiesterase-5 and Inhibitors Provide the Structural Basis for the Physiological Effects of Vardenafil and SildenafilMolecular Pharmacology, 2008
- Molecular recognition of receptor sites using a genetic algorithm with a description of desolvationJournal of Molecular Biology, 1995